Day: March 25, 2020
Nasdaq OMX Copenhagen Skjern, 25. marts 2020Nikolaj Plads 61007 København KVedhæftet fil06_Suspendering af forventningerne til 2020
MediPharm Labs Ships Cannabis Topicals and Accelerates Development to Expand Topicals Presence in Medical and Adult-Use Markets
Written by Customer Service on . Posted in Public Companies.
BARRIE, Ontario, March 25, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it has completed its first shipment of bottled cannabis topicals under a contract manufacturing agreement. The Company also announced it is accelerating its research and development program to expand the Company’s presence in the growing Canadian, and future international, medical and adult-use topicals markets.First Topical ShipmentsLeveraging the Company’s 25,000 sq. ft. licensed space, the Company completed its first shipment of topicals from its GMP-certified Barrie facility this week including the filling and packaging on behalf of its customer....
BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture
Written by Customer Service on . Posted in Public Companies.
Westport, CT, March 25, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that its majority-owned subsidiary NeuroClear Technologies, Inc. acquired the rights to develop a novel pharmaceutical to treat Coronavirus Disease 2019 (COVID-19).In a preliminary internal review, the orally administered, broad-spectrum anti-viral agent Vicromax(tm) demonstrated strong activity against COVID-19 in cell cultures in laboratory testing. In this analysis, Vicromax(tm) was added to a tissue culture assay for SARS-CO-2 coronavirus (the causative agent for COVID-19) and an anti-viral effect was observed, which led to a reduction of over 90% of infectious viruses. The Company intends to pursue...
NGS Group AB: NGS Group skjuter upp årsstämman
Written by Customer Service on . Posted in Public Companies.
Styrelsen för NGS Group AB (publ) har idag, till följd av utbrottet av coronaviruset Covid-19, beslutat skjuta upp årsstämman. Skälet är att NGS vill undvika risken för smittspridning genom att samla aktieägarna.NGS återkommer med ny kallelse till årsstämma senast fyra veckor före det nya datumet. Årsstämman kommer att hållas den 2 juni 2020 klockan 16.00.Den rådande situationen med coronaviruset kan innebära både ökade behov av våra tjänster exempelvis inom vården, men även minskad efterfrågan på våra tjänster inom specialist- och chefsrekrytering beroende på hur marknadssituationen för våra kunder utvecklas. När detta skrivs är det ännu för tidigt att uttala sig om vad effekten av Covid-19 blir på de marknader NGS verkar. NGS arbetar med fullt fokus på de möjligheter som finns och med uppdraget att lösa kundernas behov. Detta sker parallellt...
WINNEBAGO INDUSTRIES ANNOUNCES SECOND QUARTER FISCAL 2020 RESULTS
Written by Customer Service on . Posted in Public Companies.
— Strong Sales Growth Continues to Outperform the RV Industry — — Quarterly Revenues Increased 45%, including Robust Organic Growth of 13% —— Reported Quarterly Diluted EPS of $0.51, Adjusted EPS of $0.67 Up 9.8% Over Prior Year —— YTD Operating Cash Flow Up 129% Over Prior Year — — First Full Quarter of Contribution From Newmar with Integration Progressing as Planned —FOREST CITY, Iowa, March 25, 2020 (GLOBE NEWSWIRE) — Winnebago Industries, Inc. (NYSE:WGO), a leading outdoor lifestyle product manufacturer, today reported financial results for the Company’s second quarter Fiscal 2020.Second Quarter Fiscal 2020 ResultsRevenues for the Fiscal 2020 second quarter ended February 29, 2020, increased 44.9% to $626.8 million compared to $432.7 million for the...
Nokia completes acquisition of Elenion Technologies
Written by Customer Service on . Posted in Public Companies.
Press ReleaseNokia completes acquisition of Elenion Technologies25 March 2020Espoo, Finland – Nokia today announced the successful completion of its acquisition of Elenion Technologies, a U.S.-based company focusing on silicon photonics technology. The planned acquisition was originally announced February 19, 2020.Elenion’s technology expertise and unique design platform and services enable Nokia to expand its market footprint by addressing the critical and rapidly evolving optical connectivity requirements of 5G, cloud and enterprise networking. Ownership of these key assets brings time-to-market and cost advantages to Nokia’s broad portfolio of networking solutions by applying the massive scale and economies of silicon design and manufacturing to the optical supply chain.About NokiaWe create the technology to connect the world. Only...
Audited Full Year Results for the year ended 31 December 2019
Written by Customer Service on . Posted in Public Companies.
PRESS RELEASEAudited Full Year Results for the year ended 31 December 2019Revenue £68.3m (up 26.1%)Adjusted EBITDA £12.5m (up from £2.3m in 2018)Order book of future contracted revenue £124.1 million (up 13.6%)New £30m credit facilityGuildford, UK – 25 March 2020: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, today announces its audited Full Year Results for the year ended 31 December 2019.Selected Financial HighlightsDr Miroslav Reljanović, Executive Chairman of Ergomed, said: “2019 has been a transformational year for Ergomed, delivering strong financial results and executing our focused strategy to become a leading global provider of specialist services to the pharmaceutical industry. We performed strongly across the...
Cara Therapeutics Reports Clinical Updates
Written by Customer Service on . Posted in Public Companies.
– On track to report topline data for KALM-2 Phase 3 global trial of KORSUVA™ Injection in second quarter – – On track to complete interim statistical analysis for ongoing Phase 2 trial of Oral KORSUVA in atopic dermatitis in second quarter –– Timeline to submit KORSUVA Injection New Drug Application to FDA in second half of 2020 remains unchanged –STAMFORD, Conn., March 25, 2020 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that it is on track to report topline data in the second quarter of 2020 from its ongoing pivotal KALM-2 Phase 3 global trial of KORSUVA™ Injection...
Sprott Resource Holdings Inc. Business Update and Reports 2019 Annual Results
Written by Customer Service on . Posted in Public Companies.
TORONTO, March 25, 2020 (GLOBE NEWSWIRE) — (TSX: SRHI) – Sprott Resource Holdings Inc. (“SRHI” or the “Company“) today announced its operating and financial results for the year ended December 31, 2019. The Company’s principal operating business is its 70% equity interest in the producing copper mine Minera Tres Valles (“MTV“) in Salamanca, Chile. The Company’s financial statements and management’s discussion and analysis (“MD&A“) are available at www.sprottresource.com and www.sedar.com.“The events currently unfolding in our global society are generational and moving at a pace unmatched in recent history,” stated Michael Harrison, Interim President and CEO of SRHI. “The outbreak of the Coronavirus (COVID-19) has created near-term copper...
Microbix Annual General Meeting Process Update
Written by Customer Service on . Posted in Public Companies.
MISSISSAUGA, Ontario, March 25, 2020 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, provides an update about its Annual General Meeting (“AGM”). The AGM will still be held on March 31, 2020 at 1:00 pm, however due to the closure of our planned venue and alternative venues, we will be proceeding with access being provided online or via teleconference only.Due to the COVID-19 pandemic, Microbix also wants to avoid the need for in-person attendees at this year’s AGM, a goal enabled by setting-up an online link to allow shareholders to listen to the AGM and view a CEO presentation. Microbix will also provide a teleconference number, so that shareholders...